Search results
Added:
1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University,CA) is joined by Dr Neha J Pagidipati (Duke University Medical Center, US)and Dr Christopher B Granger (Duke University Medical Center, US)to discuss the results of the COORDINATE-Diabetes trial (NCT03936660).The COORDINATE-Diabetes trial is testing a multifaceted intervention to improve the care of people with type 2…
View more
Added:
6 months ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Added:
6 years ago
This video was supplied by the International Society of Cardiovascular Pharmacotherapy (ISCP) and discusesCardiovascular risk management of diabetes and SGLT2 inhibitors
Lecturer: Masayuki Yoshida, Professor of Medicine, Tokyo Medical and Dental University, Japan
Interviewer： Koji Hasegawa, Leader, Cardiovascular Clinical Research Network, National Hospital Organization,Shizuoka, Japan
View more
ACC.24: The TACT2 Trial
Added:
1 week ago
Video
Added:
2 years ago
Dr Cecilia Low Wang (Colorado Prevention Center, US) discusses the findings from the VOYAGER PAD - rivaroxaban in symptomatic PAD with and without comorbid diabetes study. The study assessed the efficacy and safety of rivaroxaban in patients with PAD with concomitant diabetes after lower extremity revascularization.
The study presented at ESC Congress 2021 showed that the efficacy of rivaroxaban…
View more
Added:
1 year ago
EASD 22 - Dr Steven Nissen (Cleveland Clinic, US) joins us to discuss the findings of the SURMOUNT-MMO trial. This study aimed to evaluate the effect of tirzepatide in type II diabetes patients who have obesity, or are overweight.
Questions:
1. What was the rationale behind this study?
2. What is the mechanism of action of Tirzepatide?
3. What was the study design?
4. What were the main outcomes…
View more
Added:
6 months ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental…
View more
Added:
1 week ago
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of…
View more
Added:
1 year ago
AHA 22 - Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, Colorado, US) joins us to discuss the findings of the BT001 Pivotal Trial, originally presented at AHA 2022.
BT001 Pivotal aimed to study the use of a mobile app that delivered nutritional cognitive behavioural therapy (nCBT) for the treatment of type II diabetes. The application targets behaviours which are associated…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology, Greg Guillory
Two late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes and prior myocardial…
View more
